Understand FDA developments & EU regulations for Biosimilars on 24th & 25th September, London

Variations in global regulatory strategy for biosimilars outside Europe, Japan and the US
By: SMi Group
 
 
Homepage-banner
Homepage-banner
July 27, 2012 - PRLog -- Book now for SMi’s fouth annual Biosimilars and Biobetters conference for your chance to network with and learn from key industry players in this fast-paced and ever-growing field. This exciting event will offer a unique opportunity for attendees to discover the latest FDA updates and EU regulations in biosimilar development; with Laura McKinley, Director, Worldwide Regulatory Strategy, Pfizer exploring the reasons behind the lack of approval in the US and regulations across Europe, Japan and the rest of the world.

With a focus on industry case studies this conference will be the perfect forum to discuss the rising development cost of biosimilars and successful marketing and pricing strategies. Heinz Haenel, Senior Project Director, Sanofi, will be present an in-depth view into Biosimilar development for recombinant human insulin with a focus on market access in developing countries.

Reasons to attend this outstanding conference include:

•   Examine the latest developments in biosimilar pipelines around the world
•   Discover the impact of recent guidelines issued by regulatory bodies such as the FDA and EMEA
•   Develop plans and methods for biosimilar and biobetter drug design and clinical testing
•   Learn about new variations in global regulatory strategies for biosimilar development
•   Evaluate current and future developments in intellectual property and patent protection
•   Hear from industry and academia on the development process from a pre-clinical perspective
•   Consider market access pathways and learn from past success stories
•   Understand and make the most of opportunities for long term growth in follow on biologics
•   Network and learn from key opinion leaders from the field

Companies already Registered include:
Harvest Moon Pharmaceuticals
Teva Pharamceuticals
Tiber Creek Partners
Amgen
Hospira UK Limited
Chiesi Farmaceutici S. P. A.
Takeda Pharmaceuticals
Frontline Pharma Consulting Ltd
Merck Research Laboratories
Pfizer
NTC pharma
Sandoz
Actavis
GlaxoSmithKline
Sanofi-Aventis
Quintiles
Abbott
Thomson Reuters
Novartis
FIOCRUZ

With limited amount of spaces ensure you book your place now!

Visit www.smi-online.co.uk/goto/biosimilars-biobetters66.asp Alternatively contact Fateja Begum on email fbegum@smi-online.co.uk or tel +44 0 207 827 6184
End
Source:SMi Group
Email:***@smi-online.co.uk Email Verified
Tags:Biologics, Biosimilars, Antibodies, Mabs
Industry:Pharmaceutical
Location:England
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
SMi Group Ltd. News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share